153559-49-0 | Bexarotene

Chemical type

• Retinoid X receptor (RXR) agonist

^[1]

• Synthetic retinoid

^[2]

Key properties

• Selective receptor agonist
• Investigated chemotherapeutic agent

^[1]

• Retinoid X receptor (RXR) agonist
• Reduces HA production by decreasing expression of HA synthases (HAS1, HAS2, HAS3) and CEMIP
• Induces apoptosis, differentiation, prevents multidrug resistance, inhibits angiogenesis and metastasis

^[2]

• Chemotherapy drug for high-risk liver hepatocellular carcinoma (HCC) patients
• Shown to have greater sensitivity in treating high-risk HCC patients
• Experimental use to inhibit liver cancer cell growth by downregulating specific lncRNAs (CASC19, LINC01138, NRAV, Z83851.1)

^[1]

• Treatment of cutaneous T-cell lymphoma (CTCL)
• Modulation of tumor microenvironment

^[2]

Classification by use

• Chemotherapy drugs
• Targeted cancer therapy agents

^[1]

• Anti-cancer agents
• Retinoids in dermatology and oncology

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Anoikis- and m6A-related lncRNA analysis to identify prognostic indicators in liver hepatocellular carcinoma, Electronic Journal of Biotechnology, Volume 79, January 2026, 100701
2. [Cite:2] Impact of Hyaluronic Acid on the Cutaneous T-Cell Lymphoma Microenvironment: A Novel Anti-Tumor Mechanism of Bexarotene, Cancers, 2025, 17(2), 324